Scholarlink

<p>The accumulation of senescent cells and their pro-inflammatory secretome (senescence-associated secretory phenotype, SASP) contributes substantially to a&#xa0;range of age-related diseases. Senotherapeutic approaches—either through modulation of the SASP using senomorphics or through selective elimination of senescent cells using senolytics—offer the prospect of disease-modifying interventions beyond symptom-directed treatment. Preclinical models consistently demonstrate functional improvements in muscle, organ, and metabolic parameters, along with extensions of healthspan. Early clinical studies have generated cautiously positive signals, particularly in idiopathic pulmonary fibrosis, chronic kidney disease, and osteoarthritis; however, interpretation remains limited by small patient cohorts, the absence of validated biomarkers, and the use of non-optimized drug candidates. Major challenges include the heterogeneity of senescent cell populations, the lack of reliable diagnostic markers, safety considerations, and regulatory requirements. The authors’ own research and the spin-off Rockfish Bio are developing more precise and selective next-generation senolytics that show encouraging efficacy in preclinical models without detectable toxicity. At the same time, circulating miRNAs are being evaluated as potential clinical biomarkers. Whether senotherapeutics ultimately reach routine clinical practice will depend on robust clinical trial data and clearly defined regulatory pathways. Commercial availability is unlikely within the next 4–6&#xa0;years; until then, their use will remain restricted to clinical trials and will require realistic, evidence-based communication with patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Senolytika: neue Wunderwaffe gegen altersassoziierte Erkrankungen?

  • 期刊论文

  • 发表日期：

    2026年1月30日

查看全文
  • Ingo Lämmermann,
  • Johannes Grillari

摘要

The accumulation of senescent cells and their pro-inflammatory secretome (senescence-associated secretory phenotype, SASP) contributes substantially to a range of age-related diseases. Senotherapeutic approaches—either through modulation of the SASP using senomorphics or through selective elimination of senescent cells using senolytics—offer the prospect of disease-modifying interventions beyond symptom-directed treatment. Preclinical models consistently demonstrate functional improvements in muscle, organ, and metabolic parameters, along with extensions of healthspan. Early clinical studies have generated cautiously positive signals, particularly in idiopathic pulmonary fibrosis, chronic kidney disease, and osteoarthritis; however, interpretation remains limited by small patient cohorts, the absence of validated biomarkers, and the use of non-optimized drug candidates. Major challenges include the heterogeneity of senescent cell populations, the lack of reliable diagnostic markers, safety considerations, and regulatory requirements. The authors’ own research and the spin-off Rockfish Bio are developing more precise and selective next-generation senolytics that show encouraging efficacy in preclinical models without detectable toxicity. At the same time, circulating miRNAs are being evaluated as potential clinical biomarkers. Whether senotherapeutics ultimately reach routine clinical practice will depend on robust clinical trial data and clearly defined regulatory pathways. Commercial availability is unlikely within the next 4–6 years; until then, their use will remain restricted to clinical trials and will require realistic, evidence-based communication with patients.